Participated · Series A · Jan 2026

AirNexis Therapeutics is focused on creating new treatments for pulmonary diseases, with an initial emphasis on chronic obstructive pulmonary disease. Its lead asset, AN01, is a dual PDE3/4 inhibitor that simultaneously drives bronchodilation and dampens inflammatory pathways, offering a synergistic mechanism of action for COPD patients. The molecule, currently in Phase 2 development, was recently in-licensed from Haisco Pharmaceutical Group, giving AirNexis worldwide rights outside China. Led by CEO Maria Fardis, the company plans to advance AN01 through global clinical trials and pursue additional indications within pulmonary medicine. The $200 million Series A financing provides the capital required to accelerate clinical development, expand regulatory activities, and build out manufacturing capabilities. No commercial revenue has yet been reported, reflecting the company’s clinical-stage status, and financial resources now largely consist of the new equity infusion.

Participated · Series A · Nov 2025

Braveheart Bio is a late clinical-stage biotechnology company focused on treating hypertrophic cardiomyopathy and related cardiac conditions. Its lead candidate, BHB-1893, is a small-molecule, selective cardiac myosin inhibitor designed to reduce over-contraction of the heart muscle and improve cardiac filling and pumping efficiency in HCM patients. HCM is one of the most common rare diseases, affecting roughly 1 in 500 people in the United States, underscoring the sizable medical need Braveheart aims to address. The company is led by President and CEO Dr. Travis Murdoch and operates out of San Francisco, California. In November 2025, Braveheart secured $185 million in Series A financing, providing substantial capital to advance late-stage clinical trials and broaden its research pipeline. The newly raised funds will be deployed to expand operations and intensify R&D efforts around BHB-1893 and potential follow-on programs. Although revenue and user metrics are not yet relevant at this clinical stage, the large Series A round positions the company to progress toward pivotal studies and eventual regulatory submissions.

Led · Series B · Jan 2025

Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and tumors. Its lead program, NRM-823, is a first-in-class T cell engager that binds a novel, highly specific tumor target expressed on multiple solid tumors. The company plans to initiate a Phase 1 clinical trial of NRM-823 in 2H 2025 and to advance other modalities against the same tumor-specific target, including antibody-drug conjugates and radiotheranostics. Normunity is building a pipeline of therapeutic antibodies, bispecific antibodies, and payload-carrying biologics derived from its proprietary target discovery process conducted in collaboration with the lab of Professor Lieping Chen at Yale. The recent $75 million Series B financing will be used to advance NRM-823 into the clinic and to broaden the pipeline of programs that address tumor-specific immune suppression. Normunity is located in Boston, MA and New Haven, CT. Normunity is creating a new class of precision immuno-oncology agents called immune normalizers that aim to free the body’s normal immunity against cancer. Its initial pipeline programs target mechanisms that drive the exclusion of T cells from immune-sensitive tumors and seek to render 'cold' tumors immune-responsive. The company was launched from an academic–biotech partnership with the Lieping Chen lab at Yale School of Medicine and leverages proprietary discovery platforms from that lab. Normunity says its collaborative, iterative model jointly interrogates and validates emerging targets preclinically and clinically. Leadership includes founding CEO Rachel Humphrey and scientific founder Lieping Chen, and the team is described as experienced in discovery and clinical advancement of cancer drugs. The Series A financing announced will enable advancement of the emerging pipeline into the clinic and expansion of the lab-based discovery platforms.

Participated · Series C · Jan 2025

Aviceda is a Cambridge, MA‑based, clinical‑stage biotech focused on ophthalmic and broader immunomodulatory therapeutics built on its High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform. Its lead asset, AVD‑104, is an intravitreal glycan‑coated nanoparticle with a dual mechanism that repolarizes inflammatory microglia/macrophages and inhibits complement cascade amplification. AVD‑104 showed proof‑of‑concept efficacy in a Phase 2a trial completed in early 2024 and is being evaluated in a fully enrolled Phase 2b/3 trial with 12‑month data expected in the second half of 2025. The company intends to use recent financing proceeds to complete the ongoing Phase 2b/3 and to support a planned pivotal Phase 3 program, and to expand into other ophthalmic indications. Aviceda also reports a broader pipeline across ophthalmology and other therapeutic areas including immunology, fibrosis, oncology, and neurology. Board and governance changes accompanying recent financing are intended to support late‑stage development and commercialization planning.

Participated · Series B · Sep 2024

OrsoBio is advancing a portfolio of mitochondrial protonophores designed to increase energy expenditure and complement GLP-1 RA–based weight-loss therapies. Its lead oral, liver-targeted candidate TLC-6740 is in a 12-week Phase 1b trial in patients with obesity, and a prior Phase 1 in healthy subjects showed safety, dose-dependent increases in energy expenditure, and improvements in lipids and insulin-resistance markers. IND-enabling studies for two additional protonophores (TLC-1180 and TLC-1235) with distinct distribution and delivery attributes are expected to complete in 2025. TLC-1180 is described as a potent, long-acting protonophore suitable for weekly oral or subcutaneous dosing; TLC-1235 is a controlled-release mitochondrial protonophore. OrsoBio also has TLC-3595 (an ACC2 inhibitor) and TLC-2716 (an LXR inverse agonist) in Phase 2a studies for type 2 diabetes, severe hypertriglyceridemia, and MASH. The company intends to use newly raised capital to accelerate clinical development across these programs. OrsoBio is a clinical-stage biopharmaceutical company developing therapies for obesity and related metabolic disorders including type 2 diabetes, NASH, and severe dyslipidemias. The company has a portfolio of four programs spanning clinical and preclinical development that target central pathways in energy metabolism. Lead programs include a liver-targeted mitochondrial protonophore (TLC-6740) moving through Phase 1b with a planned Phase 2a, a controlled-release protonophore candidate (TLC-1235) in IND-enabling work, an ACC2 inhibitor (TLC-3595) that completed a Phase 2a and is preparing for Phase 2b, an LXR inverse agonist (TLC-2716) that completed a Phase 2a with groundwork for Phase 2b, and an ACMSD inhibitor with a development candidate selected and IND-enabling activities underway. The company says the financing will enable advancement of these programs toward key clinical milestones. OrsoBio emerged from stealth last year and was founded in 2020; following the financing it has raised $97 million in total capital.